Organigram (OGI) Competitors

C$2.37

+0.01 (+0.42%)

(As of 10/15/2024 ET)

OGI vs. CMED, WEED, EMC, ICC, LEAF, MGW, BE, BLO, SL, and MJN

Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include CanniMed Therapeutics (CMED), Canopy Growth (WEED), Emblem (EMC), ICC Labs (ICC), Leaf Mobile (LEAF), Maple Leaf Green World (MGW), Beleave (BE), Cannabix Technologies (BLO), Supreme Cannabis Company Inc, (SL), and Cronos Group (MJN). These companies are all part of the "cannabis" industry.

Organigram vs.

Organigram (TSE:OGI) and CanniMed Therapeutics (TSE:CMED) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.

: Organigram presently has a consensus target price of C$3.98, suggesting a potential upside of 67.72%. Given Organigram's higher probable upside, equities analysts clearly believe Organigram is more favorable than CanniMed Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organigram
0 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.75
CanniMed Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: In the previous week, Organigram's average media sentiment score of 0.00 equaled CanniMed Therapeutics'average media sentiment score.
Company Overall Sentiment
Organigram Neutral
CanniMed Therapeutics Neutral
: CanniMed Therapeutics has lower revenue, but higher earnings than Organigram.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Organigram C$149.21M 1.72 -C$229.48M -C$2.51 -0.94
CanniMed Therapeutics N/A N/A N/A N/A N/A
: CanniMed Therapeutics has a net margin of 0.00% compared to Organigram's net margin of -153.80%. CanniMed Therapeutics' return on equity of 0.00% beat Organigram's return on equity.
Company Net Margins Return on Equity Return on Assets
Organigram -153.80% -54.53% -5.56%
CanniMed Therapeutics N/A N/A N/A
: 8.4% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: CanniMed Therapeutics received 109 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 75.85% of users gave CanniMed Therapeutics an outperform vote while only 44.86% of users gave Organigram an outperform vote.
Company Underperform Outperform
Organigram Outperform Votes
48
44.86%
Underperform Votes
59
55.14%
CanniMed Therapeutics Outperform Votes
157
75.85%
Underperform Votes
50
24.15%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
CanniMed Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Overall Sentiment
Organigram	Neutral
CanniMed Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$149.21M	1.72	-C$229.48M	-C$2.51	-0.94
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Organigram	-153.80%	-54.53%	-5.56%
CanniMed Therapeutics	N/A	N/A	N/A

Company	Underperform	Outperform
Organigram	Outperform Votes 48 44.86%	Underperform Votes 59 55.14%
CanniMed Therapeutics	Outperform Votes 157 75.85%	Underperform Votes 50 24.15%

Summary

Organigram and CanniMed Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Ad Porter & Company

The real reason Elon is fully endorsing Trump

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

Get Organigram News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGI vs. The Competition

Export to Excel

Metric	Organigram	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$257.31M	C$1.31B	C$5.49B	C$5.43B
Dividend Yield	N/A	3.10%	4.36%	5.50%
P/E Ratio	-0.94	106.55	129.82	29.50
Price / Sales	1.72	3,046.49	1,174.85	1,394.40
Price / Cash	3.85	9.97	38.28	81.32
Price / Book	0.83	3.00	4.72	3.15
Net Income	-C$229.48M	C$90.72M	C$120.06M	C$262.27M
7 Day Performance	3.49%	0.48%	3.61%	1.15%
1 Month Performance	-8.14%	-1.24%	15.68%	4.19%
1 Year Performance	47.20%	87.00%	30.06%	38.36%

Organigram Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGI Organigram	2.7671 of 5 stars	C$2.37 +0.4%	C$3.98 +67.7%	+53.9%	C$257.31M	C$149.21M	-0.94	987	Gap Up
CMED CanniMed Therapeutics	N/A	N/A	N/A	N/A	C$668.44M	N/A	0.00	147,000
WEED Canopy Growth	1.0224 of 5 stars	C$5.53 +1.3%	C$7.12 +28.7%	+488.7%	C$469.28M	C$287.10M	-0.70	2,700	Gap Up
EMC Emblem	N/A	$1.88 +1.6%	N/A	+0.0%	$245.45M	$5.71M	-9.89	N/A
ICC ICC Labs	N/A	C$1.62 -5.8%	N/A	+0.0%	C$223.64M	C$533,684.00	95.29	N/A	Gap Up
LEAF Leaf Mobile	N/A	N/A	N/A	N/A	C$198.42M	C$83.74M	58.86	150
MGW Maple Leaf Green World	N/A	C$0.79 +777.8%	N/A	+0.0%	C$111.69M	N/A	0.00	N/A	News Coverage Gap Up
BE Beleave	N/A	N/A	N/A	N/A	$0.00	N/A	0.00	N/A	High Trading Volume
BLO Cannabix Technologies	N/A	N/A	N/A	N/A	C$0.00	N/A	0.00	N/A	Gap Down
SL Supreme Cannabis Company Inc,	N/A	N/A	N/A	N/A	C$0.00	N/A	0.00	N/A	Gap Down High Trading Volume
MJN Cronos Group	N/A	C$12.15 -1.9%	N/A	+0.0%	C$1.73B	N/A	0.00	7,600